Coronavirus COVID-19 Updates: uc.edu/publichealth
Search By:
By: University of Cincinnati Cancer Center
Survivorship at the University of Cincinnati Cancer Center goes beyond treatment. Led by Elizabeth Shaughnessy, MD and Alique Topalian, PhD, MPH, both cancer survivors, the Survivorship and Supportive Services Program offers innovative, comprehensive care tailored to the unique needs of each survivor.
The first recipients of the Dr. Peter Stambrook Pilot Awards were honored at this years Cancer Research Retreat. This award honors Dr. Peter Stambrook's legacy as a cancer researcher who dedicated his career to helping young investigators.
The University of Cincinnati Cancer Center hosted its third annual Cancer Research Retreat on Friday, April 19. Attendees learned about the Cancer Center's recent progress, listened to presentations on cutting-edge cancer research in Cincinnati, and discussed ways to address local health disparities.
The University of Cincinnati Cancer Center Pilot Project Award Program is dedicated to advancing cancer research by providing pilot funding to our faculty investigators. This Spring 2024 cycle we celebrate 8 investigators whose pilot research received funding.
Tammy Mentzel, MPH, has been named Executive Director for Center Administration and Associate Director for Administration at the University of Cincinnati Cancer Center.
Andrew Waters, PhD, a basic scientist at the University of Cincinnati Cancer Center and assistant professor within the Division of Surgical Oncology and the Department of Cancer Biology at UC, runs a research lab focusing on the molecular consequences and resistance mechanisms to KRAS inhibitors.
The University of Cincinnati Cancer Center Clinical Trials Office recently opened a trial to study the efficacy of LN-145 on patients with advanced lung cancer. This treatment involves the infusion of patients’ own immune cells, tumor-infiltrating lymphocytes (TIL), to evaluate the efficacy of LN-145 as determined by objective response rates (ORR).
How will the explosion of AI impact cancer research and care? Last month, the University of Cincinnati Cancer Center held the tenth annual Charge Against Cancer Symposium on “Leveraging Artificial Intelligence and Data Sciences to Conquer Cancer” to tackle this topic.
The University of Cincinnati Cancer Center Clinical Trials Office recently opened a trial to compare a lower-than-standard dosage of a widely used treatment in newly diagnosed acute myeloid leukemia (AML) patients. This clinical trial is designed to evaluate the efficacy this dosage and treatment schedule of Venetoclax plus Azacitidine may have for newly diagnosed AML patients.
231 Albert Sabin Way, Suite 2005Cincinnati, OH 45267Phone: 513-558-2177Fax: 513-558-2666